The gap between trial and real-world tirzepatide vs semaglutide outcomes comes mostly from discontinuation and under-titration: only 25.9% of tirzepatide users reach 15 mg in practice, versus 83.5% of semaglutide users reaching 2.4 mg in the trial
She is very welcoming and has a lovely manner
These medications involve a shot taken one time every week that has been used for some time as a medication to control type 2 diabetes
Curre Res Diabetes & Obes J 2023
2 Department of Endocrinology, SANKO University Faculty of Medicine, Gaziantep, Turkey Correspondence: Nimet Ylmaz, Department of Gastroenterology, SANKO University Faculty of Medicine, Gaziantep, Turkey, Email [email protected] Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP receptor agonists are highly effective agents for the treatment of type 2 diabetes and obesity